| Wall Street Journal. Europe 1998 Stephen D. Moore |
| Title | Subject | Authors |
|---|
| Astra and Merck agree to revamp U.S. affiliate. | Business, international | Stephen D. Moore |
| Astra writes a prescription for future. | Business, international | Stephen D. Moore |
| Bayer Joins Millenium in Drug Discovery. U.S. Firm Could Be Paid as Much as $465 Million. | Business, international | Stephen D. Moore |
| Bayer reconsiders independent stance. | Business, international | Stephen D. Moore |
| Bayer to buy Chiron unit for $1.1 billion, shed Agfa, acquire stake in U.S. venture. | Business, international | Stephen D. Moore, Martin Du Bois |
| British Biotech signals a shift in its strategies. | Business, international | Stephen D. Moore |
| Ciba Specialty's chairman jogs Swiss industry. | Business, international | Stephen D. Moore |
| Ciba Specialty to trim 1,100 jobs following loss. | Business, international | Stephen D. Moore |
| Credit Suisse bets on Latin America with Garantia. | Business, international | Stephen D. Moore |
| Drug firms battle for pre-eminence in marketing of multiple sclerosis drug. | Business, international | Stephen D. Moore |
| EU lowers demand of U.K. slots to be ceded for British Air deal. | Business, international | Stephen D. Moore |
| Founder of Cortecs challenges claim he resigned voluntarily. | Business, international | Stephen D. Moore |
| French drug duo looks to next deal; Sanofi and Synthelabo seek expansion in U.S.(Sanofi S.A., Synthelabo S.A.)(Abstract) | Business, international | Stephen D. Moore, Charles Fleming |
| German Biotech sector is attracting U.S. firms. | Business, international | Stephen D. Moore |
| Goldstein of SmithKline to head British biotech. | Business, international | Stephen D. Moore |
| Hoechst ends talks with Rhone-Poulenc. | Business, international | Stephen D. Moore, Steven Lipin |
| Hoechst in pact on its paints unit. | Business, international | Stephen D. Moore |
| Hoechst seen lowering price for paints deal. | Business, international | Stephen D. Moore, Erik Portanger |
| Hoechst's vital signs get stronger. | Business, international | Stephen D. Moore |
| Merck buys stake in U.S. biotech firm; drug maker bets on experimental therapies.(Abstract) | Business, international | Stephen D. Moore |
| Novartis to change way it runs Systemix and GTI. | Business, international | Stephen D. Moore |
| Novartis to prune brand portfolio. | Business, international | Stephen D. Moore |
| Novo profit, buyback plan boost stock. | Business, international | Stephen D. Moore |
| Novo pulls plug on drug seen as key to its future. | Business, international | Stephen D. Moore |
| Pfizer gives Phytopharm a boost; pact centers on obesity treatment. | Business, international | Stephen D. Moore |
| Pharming woos investors with high-tech Barnyard. | Business, international | Stephen D. Moore |
| Pretax profit increases 7% at SmithKline Beecham. | Business, international | Stephen D. Moore |
| Rhone-Poulenc may team up with Hoechst. | Business, international | Stephen D. Moore |
| Roche Holding's net income rises 3%. | Business, international | Stephen D. Moore |
| Roche research chief bets firm's future on genetic research. | Business, international | Stephen D. Moore |
| Roche withdraws Posicor, dimming sales prospects. | Business, international | Stephen D. Moore |
| Sanofi and Synthelabo agree to merge forming a top 20 global drug maker.(Abstract) | Business, international | Stephen D. Moore, Thomas Kamm |
| SmithKline chief to quit for top Chiroscience post. | Business, international | Stephen D. Moore |
| SmithKline drops alliance with Vanguard on drugs. | Business, international | Stephen D. Moore |
| Swiss banks bet Holocaust offer restarts talks. | Business, international | Stephen D. Moore |
| Swiss banks pay the price in suit settlement. | Business, international | Stephen D. Moore |
| Swiss drug makers battle referendum on genetic research. | Business, international | Stephen D. Moore |
| Synthelabo, Monsanto unit alter deal. | Business, international | Stephen D. Moore |
| Temperature rises as Astra and Zeneca mull $35 billion deal.(Astra AB and Zeneca Group PLC)(Abstract) | Business, international | Steven Lipin, Stephen D Moore |
| Vanguard and Skyepharma sign key licensing deals. | Business, international | Stephen D. Moore |
| Viagra poses dilemma for Europe's tradition of state-funded care. | Business, international | Stephen D. Moore, Betsy McKay |
| Zeneca management shift means strategy continues. | Business, international | Stephen D. Moore |
| Zenecca narrows its focus with chemical unit offer; company decides to sell its division as sector begins to consolidate. | Business, international | Stephen D. Moore |
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
